Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus

Overview[ - collapse ][ - ]

Purpose The main purpose of this study is to know on one hand if lorazepam is more (effective) than clonazepam and on the other hand if lorazepam is also effective as the association clonazepam + fosphenytoin in out-of-hospital treatment of the generalized convulsive status epilepticus in adult patients.
ConditionStatus Epilepticus
Epilepsy
InterventionDrug: Clonazepam
Drug: Fosphenytoin
Drug: Placebo
Drug: Lorazepam
PhasePhase 3
SponsorAssistance Publique - Hôpitaux de Paris
Responsible PartyAssistance Publique - Hôpitaux de Paris
ClinicalTrials.gov IdentifierNCT01870024
First ReceivedJune 3, 2013
Last UpdatedJuly 26, 2013
Last verifiedJuly 2013

Tracking Information[ + expand ][ + ]

First Received DateJune 3, 2013
Last Updated DateJuly 26, 2013
Start DateJune 2013
Estimated Primary Completion DateJune 2015
Current Primary Outcome MeasuresPercentage of patient with a cessation of seizures and absence of recurrence [Time Frame: between 20 and 60 minutes after the beginning of the treatment] [Designated as safety issue: No]Percentage of patient with a cessation of seizures and absence of recurrence from 20 minutes until 60 minutes after the beginning of the treatment
Current Secondary Outcome Measures
  • Duration between the first cessation and the recurrence of seizures [Time Frame: up to 60 minutes] [Designated as safety issue: No]Duration between the first cessation and the recurrence of seizures
  • Percentage of patients having had a second injection of benzodiazepine [Time Frame: up to 60 minutes] [Designated as safety issue: No]Percentage of patients having had a second injection of benzodiazepine
  • Percentage of patients having had an injection of the second line treatment [Time Frame: up to 60 minutes] [Designated as safety issue: No]Percentage of patients having had an injection of the second line treatment (i.e. Fosphenytoin or barbiturate)
  • Percentage of patients having a general anesthesia for refractory status epilepticus [Time Frame: up to 60 minutes] [Designated as safety issue: No]Percentage of patients having a general anesthesia for refractory status epilepticus
  • Percentage of patients having had a side effect [Time Frame: up to 60 minutes] [Designated as safety issue: No]Percentage of patients having had a side effect (low blood pressure, arrhythmias)
  • Percentage of patients having been mechanically ventilated [Time Frame: up to 60 minutes] [Designated as safety issue: No]Percentage of patients having been mechanically ventilated in pre-hospital setting
  • Glasgow Coma Scale [Time Frame: 60 minutes] [Designated as safety issue: No]Glasgow Coma Scale on arrival at the hospital
  • Mortality [Time Frame: up to 60 minutes] [Designated as safety issue: No]Mortality in pre-hospital setting
  • Mortality [Time Frame: up to Day 30] [Designated as safety issue: No]Mortality in hospital until J30 (if the patient still hospitalized)
  • Length of stay in Intensive Care Unit [Time Frame: up to Day 30] [Designated as safety issue: No]Length of stay in Intensive Care Unit
  • Length of stay in hospital [Time Frame: up to Day 30] [Designated as safety issue: No]Length of stay in hospital

Descriptive Information[ + expand ][ + ]

Brief TitleComparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Official TitleComparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients
Brief Summary
The main purpose of this study is to know on one hand if lorazepam is more (effective) than
clonazepam and on the other hand if lorazepam is also effective as the association
clonazepam + fosphenytoin in out-of-hospital treatment of the generalized convulsive status
epilepticus in adult patients.
Detailed Description
Background: Early and rapid termination of status epilepticus with intravenous
administration of benzodiazepines only or its association with other antiepileptic drug
improves outcomes. Our out-of-hospital study aims to demonstrate on one hand the superiority
of lorazepam compared with clonazepam and on the other hand the efficacy at least equivalent
of lorazepam in comparison with the association clonazepam + fosphenytoin. If these
hypotheses are demonstrated, the out-of-hospital treatment of the status epilepticus by
lorazepam in monotherapy would then be strongly recommended, considering its efficacy and
the simplicity of administration in the context of the pre-hospital emergency.Objective: To
compare the efficacy of Lorazepam with that of Clonazepam and its association with
Fosphenytoin for the treatment of out-of-hospital status epilepticus.

Participating centers: 38 prehospital emergency services employing mobile intensive care
units and located in urban areas in France participated in this study. In France, the
management of out-of-hospital medical emergencies is under the responsibility of the Service
d'Aide Medicale Urgente (SAMU). Mobile intensive care units are staffed by an attending
emergency physician or anesthesiologist, a nurse, and an ambulance driver. The study is
coordinated by the prehospital emergency service of Lariboisiere Hospital, University Paris
7 (Paris, France)

Number of patients: 522 patients; 174 patients by group.

Duration of the study: The total duration planned is of 24 months Intermediate analysis: An
intermediate analysis is planned while 261 patients will be included (50 % of the
inclusions).Duration of participation of every patient: 24 hours Data collection:
prehospital data recording during the 60 min period of the study, and intrahospital data
recording by the medical report of hospitalization.

Methodology: Multicenter, randomized, double-blind trial with 3 arms.

Main criteria of evaluation: the cessation of the status epilepticus and the absence of
recurrence from T20 minutes until T60 minutes after the beginning of the treatment.

The cessation of the status epilepticus is defined by the stop of any motor activity and any
seizures or convulsive movements. The absence of recurrence is defined by the not occurrence
of a new seizures after a period of cessation.
Study TypeInterventional
Study PhasePhase 3
Study DesignAllocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Condition
  • Status Epilepticus
  • Epilepsy
InterventionDrug: Clonazepam
clonazepam 0,015 mg/kg
Drug: Fosphenytoin
fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
Drug: Placebo
placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
Drug: Lorazepam
lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
Study Arm (s)
  • Active Comparator: 1: Lorazepam + Placebo
    [ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
  • Active Comparator: 2: Clonazepam + Placebo
    [ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
  • Active Comparator: 3: Clonazepam + Fosphenytoin
    [ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Recruitment Information[ + expand ][ + ]

Recruitment StatusRecruiting
Estimated Enrollment522
Estimated Completion DateJune 2015
Estimated Primary Completion DateJune 2015
Eligibility Criteria
Inclusion Criteria:

- Patients aged 18 years or older

- Out-of-hospital management

- presenting one of the criteria below noticed by the physician of the mobile intensive
care unit:

1. convulsive seizures at the time of treatment and were reported by reliable
witnesses to have been continuously convulsing for longer than 5 minutes,
without regaining consciousness, or

2. if they were having more than 2 repeated convulsive seizures at the time of
treatment without regaining consciousness

Exclusion Criteria:

- Patient having been already included in the study during a previous episode of status
epilepticus

- Patient having already received before the arrival of the mobile intensive care unit
one of theses studied drugs (lorazepam, clonazepam or fosphenytoin or phenytoin)

- Latent status epilepticus in deep coma

- Cerebral anoxia (post cardio respiratory arrest)

- Severe head trauma

- Patient presenting convulsive seizures of psychogenic origin

- Lennox Gastaut's syndrome

- Decision of urgent intubation

- Patients of more than 110 kg ( estimated weight

- Heart rate < 60 bpm or > 150 bpm

- Systolic Blood Pressure < 90 mmHg

- Atrioventricular block of 2nd or 3rd degree

- Ventricular tachycardia or ventricular fibrillation

- Sensibility known about benzodiazepines, fosphenytoin, phenytoin, other hydantoins,
or barbiturate

- Contraindication known about benzodiazepines (severe respiratory failure, severe
acute hepatic failure, myasthenia, syndrome of sleep apnea, glaucoma with closed
angle

- Contraindication known about fosphenytoin (intermittent acute porphyry)

- Contraindication known about barbiturate (porphyry, severe respiratory failure,
current treatment by saquinavir, ifosfamide and voriconazole, in association with
millepertuis)

- Person unaffiliated in a National Social Security Insurance

- Pregnant or breast-feeding Woman

- Impossibility to put an intravenous or intra-osseous catheter for the treatment
injection

- Absence of nurse in the mobile intensive care unit.
GenderBoth
Ages18 Years
Accepts Healthy VolunteersNo
ContactsContact: Papa GUEYE, MD
33 1 49 95 61 61
papa.gueye@lrb.aphp.fr
Location CountriesFrance

Administrative Information[ + expand ][ + ]

NCT Number NCT01870024
Other Study ID NumbersP110123
Has Data Monitoring CommitteeNo
Information Provided ByAssistance Publique - Hôpitaux de Paris
Study SponsorAssistance Publique - Hôpitaux de Paris
CollaboratorsNot Provided
Investigators Principal Investigator: Papa GUEYE, MD, PhD Assistance Publique - Hôpitaux de ParisPrincipal Investigator: François CONCINA, MD CHU Toulouse - Hôpital Purpan
Verification DateJuly 2013

Locations[ + expand ][ + ]

Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière
Paris, France, 75010
Contact: Papa GUEYE, MD, PhD | 33 1 49 95 61 61 | papa.gueye@lrb.aphp.fr
Principal Investigator: Papa GUEYE, MD, PhD
Recruiting